NCT04670523 Early Postoperative Day 0 Chest Tube Removal After Thoracoscopic Minor Surgeries
| NCT ID | NCT04670523 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Lung Pathologies of Unclear Etiology |
| Study Type | INTERVENTIONAL |
| Enrollment | 304 participants |
| Start Date | 2023-01-06 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 304 participants in total. It began in 2023-01-06 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The safe conditions for early chest tube removal have been progressively questioned and redefined around reliable digital air flow criteria and extension of liquid threshold accepted. Nevertheless, in current practice, the chest tube remains in restricting early mobilization and optimal compliance with ERAS programme, during the first crucial 24 h after surgery. Thus, to go further, the investigators decide to assess in this study the safety of POD 0 chest tube removal after minor thoracic operations in patients in health condition tolerating operation and anesthesia.
Eligibility Criteria
Inclusion Criteria: 1. Thoracoscopic extra-anatomical lung resection (surgical lung biopsy) 2. Thoracoscopic pleural biopsy 3. Signed consent 4. Age of majority Exclusion Criteria: 1. Anatomical resection 2. Empyema 3. Pleural effusion 4. Pleurodesis 5. Vulnerable persons (Pregnant women, Children and adolescents)
Contact & Investigator
Patrick Dorn, PD
STUDY DIRECTOR
Chief, Department of General Thoracic Surgery, Inselspital
Frequently Asked Questions
Who can join the NCT04670523 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Lung Pathologies of Unclear Etiology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04670523 currently recruiting?
Yes, NCT04670523 is actively recruiting participants. Contact the research team at patrick.dorn@insel.ch for enrollment information.
Where is the NCT04670523 trial being conducted?
This trial is being conducted at Bern, Switzerland.
Who is sponsoring the NCT04670523 clinical trial?
NCT04670523 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Patrick Dorn, PD at Chief, Department of General Thoracic Surgery, Inselspital. The trial plans to enroll 304 participants.